{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:44Z","timestamp":1786118924699,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:p>\n                    This study aimed to validate the preoperative gastric cancer immune prognostic score (GCIPS) as a prognostic biomarker in resectable gastric cancer (GC). We retrospectively analyzed 226 GC patients undergoing radical resection. The optimal cutoff value of the GCIPS was determined by receiver operating characteristic curve analysis, and patients were stratified accordingly to assess its prognostic value for recurrence-free survival and overall survival. The GCIPS was calculated using preoperative blood parameters. Using receiver operating characteristic-derived cutoff (2.840), patients were stratified into high- and low-GCIPS groups. The high-GCIPS group showed significantly poorer tumor differentiation (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Kaplan\u2013Meier analysis revealed that high GCIPS was associated with worse 5-year recurrence-free survival (hazard ratio\u2005=\u20052.856,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and overall survival (hazard ratio\u2005=\u20053.222,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Multivariate analysis confirmed GCIPS as an independent predictor for both outcomes after adjusting for tumor-node-metastasis stage and differentiation. The GCIPS is a robust, independent prognostic biomarker derived from routine blood tests, offering a practical tool for risk stratification and guiding individualized management in GC after radical resection.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048128","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:01:39Z","timestamp":1774036899000},"page":"e48128","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative gastric cancer immune prognostic score (GCIPS) as a novel biomarker for predicting survival in gastric cancer patients after radical resection: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Xiaosheng","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Jingdezhen First People\u2019s Hospital, Jingdezhen, Jiangxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Jingdezhen First People\u2019s Hospital, Jingdezhen, Jiangxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Jingdezhen First People\u2019s Hospital, Jingdezhen, Jiangxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260422","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer.","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R3-20260422","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer.","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London, England)"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"suppl 5","key":"R6-20260422","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification.","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta pathologica et microbiologica Scandinavica"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.annonc.2021.05.803","article-title":"Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.","volume":"32","author":"Shitara","year":"2021","journal-title":"Ann Oncol"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432.","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the `Immunoscore\u2019 in the classification of malignant tumours.","volume":"232","author":"Galon","year":"2014","journal-title":"J Pathol"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"e12378","DOI":"10.1002\/2056-4538.12378","article-title":"Gastric cancer immune microenvironment score predicts neoadjuvant chemotherapy efficacy and prognosis.","volume":"10","author":"Zhao","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"103128","DOI":"10.4251\/wjgo.v17.i4.103128","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer: enhancing clinical relevance.","volume":"17","author":"Sundararaju","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12876-025-04056-x","article-title":"Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis.","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"e33930","DOI":"10.1097\/MD.0000000000033930","article-title":"Monocyte-to-lymphocyte ratio as a determinant of survival in patients with gastric cancer undergoing gastrectomy: a cohort study.","volume":"102","author":"An","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/medicina61050785","article-title":"Association of systemic inflammatory response index and prognostic nutritional index scores with sarcopenia in patients with metastatic gastric cancer.","volume":"61","author":"Kanbur","year":"2025","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/biomedicines12030491","article-title":"The gastric cancer immune prognostic score (GCIPS) shows potential in predicting an unfavorable prognosis for gastric cancer patients undergoing immune checkpoint inhibitor treatment.","volume":"12","author":"Zuo","year":"2024","journal-title":"Biomedicines"},{"issue":"Suppl 1","key":"R18-20260422","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1007\/s10875-012-9847-0","article-title":"Cancer-related inflammation.","volume":"33","author":"Candido","year":"2013","journal-title":"J Clin Immunol"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumor progression and metastasis.","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting.","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis.","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation.","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system.","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer.","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2007-01-065995","article-title":"Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.","volume":"110","author":"Palumbo","year":"2007","journal-title":"Blood"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis.","volume":"39","author":"Jiang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment.","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome.","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","article-title":"The interactions between inflammation and coagulation.","volume":"131","author":"Esmon","year":"2005","journal-title":"Br J Haematol"},{"key":"R32-20260422","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"R33-20260422","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer.","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"Suppl 2","key":"R34-20260422","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0049-3848(10)70010-4","article-title":"Tissue factor in cancer progression and angiogenesis.","volume":"125","author":"Ruf","year":"2010","journal-title":"Thromb Res"},{"key":"R35-20260422","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/fon.09.136","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.","volume":"6","author":"Roxburgh","year":"2010","journal-title":"Future Oncol (London, England)"},{"key":"R36-20260422","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-015-1403-x","article-title":"The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.","volume":"15","author":"Jiang","year":"2015","journal-title":"BMC Cancer"},{"key":"R37-20260422","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.critrevonc.2017.06.002","article-title":"The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis.","volume":"116","author":"Dolan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R38-20260422","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.21873\/anticanres.12781","article-title":"Preoperative prognostic nutritional index predicts long-term outcome in gastric cancer: a propensity score-matched analysis.","volume":"38","author":"Hirahara","year":"2018","journal-title":"Anticancer Res"},{"key":"R39-20260422","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma.","volume":"513","year":"2014","journal-title":"Nature"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:56:58Z","timestamp":1786035418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048128","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}